PLUVIA AS

Facts

Source: Firmafakta, with business data from public registers.

organisasjonsnummer:

916635559

navn:

PLUVIA AS

organisasjonsform:

kode:

AS

beskrivelse:

Aksjeselskap

naeringskode1:

kode:

72.100

beskrivelse:

Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk

antallAnsatte:

5

hjemmeside:

www.pluviabiotech.com

epostadresse:

info@pluviabiotech.com

telefon:

not reported by source

forretningsadresse:

adresse:

Thormøhlens gate 51

poststed:

BERGEN

postnummer:

5006

kommune:

BERGEN

stiftelsesdato:

2015-11-17

registreringsdatoenhetsregisteret:

2016-02-11

aktivitet:

Medisin. Utvikle metode for medisinsk behandling av sykdom.

vedtektsfestetFormaal:

Utvikle human medisin og det som hermed hører til.

View the address in Geonorge

Board and other roles

Source: Firmafakta. Also see the separate Brønnøysund lookup under related lookups.

Daglig leder

• Daglig leder: Torgeir Vaage

Regnskapsfører

• Regnskapsfører: ECIT SERVICES AS

Revisor

• Revisor: CEDRA NORGE MOMENTUM AS

Styre

• Styremedlem: Aurora Martinez
• Styremedlem: Randi Elisabeth Taxt
• Styremedlem: Birgitte Villmo
• Styremedlem: Maija Slaidina
• Styremedlem: Hilde Furberg
• Styrets leder: Sveinung Hole
• Varamedlem: Øivind Enger

Owners

Source: Firmafakta shareholder dataset.

1. SARSIA SEED FOND II AS – 30.62 % (40903 shares, share class: Ordinære aksjer)
2. TROND MOHN FORSKNINGSSTIFTELSE – 28.93 % (38645 shares, share class: Ordinære aksjer)
3. VESTLANDETS INNOVASJONSSELSKAP AS – 16.11 % (21520 shares, share class: Ordinære aksjer)
4. INVESTINOR DIREKTE AS – 12.89 % (17218 shares, share class: Ordinære aksjer)
5. AURORA MARTINEZ – 4.01 % (5355 shares, share class: Ordinære aksjer)
6. OSCAR AUBI CATEVILLA – 2.29 % (3060 shares, share class: Ordinære aksjer)
7. JARL UNDERHAUG – 1.72 % (2295 shares, share class: Ordinære aksjer)
8. LARS SKJÆRVEN – 1.72 % (2295 shares, share class: Ordinære aksjer)
9. MING YING – 0.86 % (1148 shares, share class: Ordinære aksjer)
10. KNUT TEIGEN – 0.86 % (1147 shares, share class: Ordinære aksjer)

Fetch a longer owner list

Company holdings

No holdings found.

Grants and support

Sources provided through Firmafakta: Innovation Norway, the EU, the Research Council of Norway and SkatteFUNN.

Innovasjon Norge (2)

2 results

1. fylkesnavn:

   Hordaland

   kommunenavn:

   Bergen

   org_nr:

   916635559

   bedriftsnavn:

   PLUVIA AS

   virkemiddelkategori:

   Oppstartstilskudd

   underkategori:

   Landsdekkende etablerertilskudd

   innvilget_belop:

   100000

   innvilget_dato:

   26.08.16

   beslutningsenhet:

   IN Kommersialisering og vekst

   naringshovedgruppe:

   N - Faglig, vitenskapelig og teknisk tjenesteyting

   naring:

   72.100 Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk

   type_finansiering:

   Tilskudd

2. fylkesnavn:

   Hordaland

   kommunenavn:

   Bergen

   org_nr:

   916635559

   bedriftsnavn:

   PLUVIA AS

   virkemiddelkategori:

   Innovasjonstilskudd

   underkategori:

   Tilskudd til EU-rådgivning

   innvilget_belop:

   454000

   innvilget_dato:

   20.12.16

   beslutningsenhet:

   IN Hordaland

   naringshovedgruppe:

   N - Faglig, vitenskapelig og teknisk tjenesteyting

   naring:

   72.100 Forskning og eksperimentell utvikling innenfor naturvitenskap og teknikk

   type_finansiering:

   Tilskudd

EU-tildelinger (0)

No registered grants.

Forskningsrådet (3)

3 results

1. id:

   48057

   prosjektnummer:

   282238

   prosjekttittel:

   Development of innovative pharmacological chaperone therapy for phenylketonuria

   prosjektstart:

   2018

   prosjektslutt:

   2022

   prosjektansvarlig_navn:

   PLUVIA AS

   organisasjonsnummer:

   916635559

   sokt_belop:

   Bioteknologi

   tildelt_belop:

   0.0

   virkemiddel:

   Programmer

   aktivitet:

   Brukerstyrte innovasjonsprogrammer

2. id:

   51920

   prosjektnummer:

   290886

   prosjekttittel:

   Phenylketonuria as a paradigm disease to understand protein instability in conformational disorders and to develop chaperoning therapies

   prosjektstart:

   2018

   prosjektslutt:

   2022

   prosjektansvarlig_navn:

   PLUVIA AS

   organisasjonsnummer:

   916635559

   sokt_belop:

   Medisinsk biokjemi

   tildelt_belop:

   3.66

   virkemiddel:

   Frittstående prosjekter

   aktivitet:

   Andre frittstående prosjekter

3. id:

   42768

   prosjektnummer:

   270286

   prosjekttittel:

   Novel therapy for PKU: Candidate Drug Selection

   prosjektstart:

   2016

   prosjektslutt:

   2016

   prosjektansvarlig_navn:

   PLUVIA AS

   organisasjonsnummer:

   916635559

   sokt_belop:

   Tverr/flerfaglig teknologi og andre fagområder

   tildelt_belop:

   0.0

   virkemiddel:

   Nettverkstiltak

   aktivitet:

   Internasjonale nettverkstiltak

SkatteFUNN (3)

3 results

1. id:

   40293

   innsendt_dato:

   2016-08-22

   prosjektnummer:

   264506

   bedriftsnavn:

   PLUVIA AS

   prosjekttittel:

   Innovativ terapi for PKU pasienter - utvikling frem til legemiddelkandidat

   organisasjonsnummer:

   916635559

   fylke:

   Vestland

   kommunenavn:

   Bergen

   poststed:

   BERGEN

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2016-09-19

   prosjekt_fra_ar:

   2016

   prosjekt_til_ar:

   2018

   sammendrag:

   not reported by source

2. id:

   54185

   innsendt_dato:

   2019-08-21

   prosjektnummer:

   305593

   bedriftsnavn:

   PLUVIA AS

   prosjekttittel:

   Innovativ terapi for PKU pasienter - utvikling frem til klinikk

   organisasjonsnummer:

   916635559

   fylke:

   Vestland

   kommunenavn:

   Bergen

   poststed:

   BERGEN

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2019-09-12

   prosjekt_fra_ar:

   2019

   prosjekt_til_ar:

   2021

   sammendrag:

   Phenylketonuria (PKU) is an inborn genetic disease, affecting 1:10 000 children. Genetic diseases are caused by gene mutations that lead to destabilization, misfolding and loss of function of key proteins. In PKU, mutations affecting the enzyme phenylalanine hydroxylase (PAH) make the patients unable to process the amino acid phenylalanine - which is commonly found in food, such as meat, fish and dairy. There is no cure for the disease, and it is usually treated with a strict, lifelong diet. All PKU patients will need to follow a strict medical diet, avoiding food containing phenylalanine throughout their entire life and follow medical surveillance. The treatments available today are very burdensome for patients, often effective only for a limited proportion of patient and require maintenance of a medical diet. If the disease stays untreated, it might lead to severe physical and psychological disability, including seizures, behavioural problems and mental disorders. A research team from the University of Bergen has discovered small molecules that could be used to treat the PKU disease. These molecules, called pharmacological chaperones, are able to prevent and correct loss of function of PAH. Throughout the years, the research team has gained substantial knowledge and understanding on how mutations from PKU patients are affecting our molecular target PAH. The project is now developing a new pharmacological chaperone based therapy for PKU patients. In the next years, Pluvia hopes to develop a molecule that is advanced enough to be taken to the clinic. The potential of novel pharmacological chaperones-based therapies for the correction of the genetic disorders has also been proven for other diseases, such as cystic fibrosis, a life threatening disease affecting lung function, and Fabry disease, a rare genetic disorder.

3. id:

   65078

   innsendt_dato:

   2022-08-07

   prosjektnummer:

   338936

   bedriftsnavn:

   PLUVIA AS

   prosjekttittel:

   Innovativ terapi for PKU pasienter - utvikling frem til klinikk

   organisasjonsnummer:

   916635559

   fylke:

   Vestland

   kommunenavn:

   Bergen

   poststed:

   BERGEN

   soknad_godkjent:

   JA

   soknad_avslatt:

   NEI

   vedtaksdato:

   2022-11-21

   prosjekt_fra_ar:

   2022

   prosjekt_til_ar:

   2024

   sammendrag:

   Phenylketonuria (PKU) is an inborn genetic disease, affecting 1:10 000 children. Genetic diseases are caused by gene mutations that lead to destabilization, misfolding and loss of function of key proteins. In PKU, mutations affecting the enzyme phenylalanine hydroxylase (PAH) make the patients unable to process the amino acid phenylalanine - which is commonly found in food, such as meat, fish and dairy. There is no cure for the disease, and it is usually treated with a strict, lifelong diet. All PKU patients will need to follow a strict medical diet, avoiding food containing phenylalanine throughout their entire life and follow medical surveillance. The treatments available today are very burdensome for patients, often effective only for a limited proportion of patient and require maintenance of a medical diet. If the disease stays untreated, it might lead to severe physical and psychological disability, including seizures, behavioural problems and mental disorders. A research team from the University of Bergen has discovered small molecules that could be used to treat the PKU disease. These molecules, called pharmacological chaperones, are able to prevent and correct loss of function of PAH. Throughout the years, the research team has gained substantial knowledge and understanding on how mutations from PKU patients are affecting our molecular target PAH. The project is now developing a new pharmacological chaperone based therapy for PKU patients. In the next years, Pluvia hopes to develop a molecule that is advanced enough to be taken to the clinic. The potential of novel pharmacological chaperones-based therapies for the correction of the genetic disorders has also been proven for other diseases, such as cystic fibrosis, a life threatening disease affecting lung function, and Fabry disease, a rare genetic disorder.

Subunits

• PLUVIA AS (916727747)

Open positions

count:

0

stillinger:

No results.

Related lookups

• Doffin notices where PLUVIA AS is the buyer
• Search broadly for PLUVIA AS in Doffin
• Open positions related to PLUVIA AS
• Latest financial statement
• Patents and trademarks
• Official entity information from the Brønnøysund Register Centre
• Official roles from the Brønnøysund Register Centre
• Corporate group structure from the Brønnøysund Register Centre